One-third of older patients with end-stage kidney disease received an arteriovenous fistula within 6 months of starting ...
In a recent study of older patients with end-stage kidney disease living in Europe, researchers found o ne-third received an ...
An investigational product called Acellular Tissue Engineered Vessel demonstrated superior hemodialysis vascular access outcomes compared with AVFs in a phase 3 trial. A bioengineered human tissue ...
Approval for Xeltis’s aXess device was based on pivotal trial data that demonstrated 79% secondary patency and a patency ...
Pervasis Therapeutics Announces Promising Efficacy Results from Phase 1 and 2 Clinical Trials of Vascugel® in Dialysis Patients Needing Permanent AV Access, Data Builds on Compelling Safety Findings ...
FAIRWAY, Kan.--(BUSINESS WIRE)--Flow Forward Medical Inc. (Flow Forward), a medical device company focused on improving outcomes for hemodialysis patients through the rapid creation of high-quality ...
This requires durable access to a blood vessel site where the dialysis machine can remove and return blood. Such access is created when a surgeon attaches a vein to an artery in the patient. The ...
In a trial, an acellular tissue engineered vessel had superior functional patency for hemodialysis with acceptable safety compared with an arteriovenous fistula in high-risk patients. An acellular ...
Vascular Therapies Announces Clinical Results From Its Phase 3 Randomized Multicenter Clinical Trial
CRESSKILL, N.J.--(BUSINESS WIRE)--Vascular Therapies, a privately held biotechnology company is developing Sirogen™, a proprietary sirolimus formulation for intraoperative local drug delivery to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results